Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Bray

Podiatrist Newark, DE Doctor of Podiatric Medicine

NPI 1558378620 CMS profile 578248

324 E Main St, Ste 201, Newark, DE 19711

Open in the dashboard

General payments

$6,537

110 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Bray of Newark, DE is reported in the CMS Open Payments database as having received $6,537 across 110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $706 17
2024 General $709 19
2023 General $1,344 26
2022 General $1,702 31
2021 General $1,384 7
2020 General $150 4
2019 General $542 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Bray
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to James Bray were reported at $706. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year James Bray Podiatrist median Middle half National median
2019 $542 $196 $72–$601 $163
2020 $150 $118 $38–$335 $114
2021 $1,384 $169 $57–$573 $132
2022 $1,702 $220 $74–$782 $149
2023 $1,344 $208 $71–$635 $160
2024 $709 $237 $87–$681 $164
2025 $706 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Liberty Surgical, Inc $1,796 6 payments
  2. Smith+Nephew, Inc. $1,479 46 payments
  3. Treace Medical Concepts, Inc. $1,134 15 payments
  4. Medical Device Business Services, Inc. $759 5 payments
  5. Stryker Corporation $377 7 payments
  6. Bioventus LLC $156 2 payments
  7. Cardiovascular Systems Inc. $128 1 payment
  8. Medtronic, Inc. $112 2 payments
  9. Zimmer Biomet Holdings, Inc. $108 3 payments
  10. Organogenesis Inc. $76 3 payments
  11. Other $411 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,401 102 payments
  2. Education $1,606 2 payments
  3. Travel and Lodging $1,530 6 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM $917 14 payments
  2. GRAFIX PL Other Advanced Wound Management $631 17 payments
  3. STRAVIX $267 6 payments
  4. CUT GUIDE $216 1 payment
  5. GRAFIX PL Other Advanced Wound Management $171 3 payments
  6. EASYFUSE $138 1 payment
  7. Diamondback Peripheral $128 1 payment
  8. PROPHECY $101 2 payments
  9. INTELLIS ADAPTIVESTIM $97 1 payment
  10. Stratum Foot Plating System $94 2 payments
  11. Other $1,538 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

189

Median for Podiatry: 160

Drug cost

$3,236

Median for Podiatry: $2,368

Branded share of claims

19%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 30 $1,735
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 36 $347
Terbinafine Hcl Generic 13 $273
Cephalexin Generic 13 $189
Clindamycin Hcl Generic 16 $149
Gabapentin Generic 13 $129
Doxycycline Hyclate Generic 12 $128
Naproxen Generic 22 $114
Tramadol Hcl Generic 12 $103
Colchicine Generic 22 $68

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$119,132

Medicare's payments for the services billed

Medicare patients

376

Average age 77

Services billed

1,309

204 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 47%
Chronic kidney disease 38%
Ischemic heart disease 25%
Atrial fibrillation 23%
Depression 23%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record